Over expression of HER2 seen in some cases of breast cancer is an indicator of poor prognosis for these patients.5 Since 2000, HER2 test has been approved by FDA and is used in the management and follow-up of patients with metastatic breast cancer. Here, ERBB2 is linked to breast cancer.